	US 12,428,643 B2
	Treating herpesvirus-mediated intestinal dysfunction for prevention of age-related neurodegeneration
Richelle Gayle Cutler, Ann Arbor, MI (US)
Assigned to Battle Biotech L.L.C., Ypsilanti, MI (US)
Filed by Battle Biotech, LLC, Ann Arbor, MI (US)
Filed on Dec. 10, 2019, as Appl. No. 16/709,607.
Prior Publication US 2021/0171952 A1, Jun. 10, 2021
Int. Cl. C12N 15/113 (2010.01); A61K 9/00 (2006.01); C12N 1/20 (2006.01); A61K 45/06 (2006.01)

CPC C12N 15/1133 (2013.01) [C12N 1/20 (2013.01); A61K 9/0053 (2013.01); A61K 45/06 (2013.01); C12N 2310/122 (2013.01); C12N 2310/141 (2013.01)]

17 Claims

1. A method of preventing or treating a human herpesvirus-infection in the gastrointestinal tract of a subject by oral administration of exosomes containing antiviral factors derived from colonic fibroblasts selected from the group consisting of miRNA, shRNA, mRNA, lncRNA, and a combination thereof.